Sander Van Deventer is both partner with Forbion Capital Partners, and professor of Experimental Medicine at the University of Amsterdam Medical School (AMC).
Sander was part of the original ABN AMRO Capital Life Sciences (AAC LS) team, before it became the independent body Forbion.
He joined as venture partner at AAC LS in 2004. Sander has significant experience in the medical and life sciences field. As such, he has been a consultant to all major pharma and to a significant number of large biotech companies.
He is co-founder of the gene therapy company Amsterdam Molecular Therapeutics, and currently holds a part-time position on the company's board as Chief Scientific Officer.
In 1995, Sander became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam, where he worked on therapeutic signal transduction inhibition, gene therapy, and (genetically engineered) probiotics.